Axicabtagene ciloleucel compared to tisagenlecleucel for the treatment of aggressive B-cell lymphoma.

MLA

Kwon, Mi, et al. “Axicabtagene Ciloleucel Compared to Tisagenlecleucel for the Treatment of Aggressive B-Cell Lymphoma.” Haematologica, vol. 108, no. 1, Jan. 2023, pp. 110–21. EBSCOhost, https://doi.org/10.3324/haematol.2022.280805.

APA

Kwon, M., Iacoboni, G., Reguera, J. L., Corral, L. L., Morales, R. H., Ortiz-Maldonado, V., Guerreiro, M., Caballero, A. C., Domínguez, M. L. G., Pina, J. M. S., Mussetti, A., Sancho, J. M., Bastos-Oreiro, M., Catala, E., Delgado, J., Henriquez, H. L., Sanz, J., Calbacho, M., Bailén, R., … Barba, P. (2023). Axicabtagene ciloleucel compared to tisagenlecleucel for the treatment of aggressive B-cell lymphoma. Haematologica, 108(1), 110–121. https://doi.org/10.3324/haematol.2022.280805

Chicago

Kwon, Mi, Gloria Iacoboni, Juan Luis Reguera, Lucía López Corral, Rafael Hernani Morales, Valentín Ortiz-Maldonado, Manuel Guerreiro, et al. 2023. “Axicabtagene Ciloleucel Compared to Tisagenlecleucel for the Treatment of Aggressive B-Cell Lymphoma.” Haematologica 108 (1): 110–21. doi:10.3324/haematol.2022.280805.